Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2012

Joseph Richard W, Sullivan Ryan J, Harrell Robyn, Stemke-Hale Katherine, Panka David, Manoukian George, Percy Andrew, Bassett Roland L, Ng Chaan S, Radvanyi Laszlo, Hwu Patrick, Atkins Michael B, Davies Michael A

Abstract excerpt

The purpose of this study is to identify clinical and molecular characteristics of melanoma patients that predict response to high-dose interleukin-2 (HD IL-2) to improve patient selection for this approved but toxic therapy. We reviewed the records of 208 patients with unresectable stage III/IV melanoma treated with HD IL-2 at the University of Texas M.D. Anderson Cancer Center (n=100) and the Beth Israel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Genes, ras

Share to Immunotherapy

Share to Interleukin-2

Share to Melanoma

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 22130161
DOI: 10.1097/CJI.0b013e3182372636
PMCID: PMC3241890

Genes

NRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.PMID 22130161Read ↗

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.Semantic proximity Read ↗

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.Semantic proximity Read ↗

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.Semantic proximity Read ↗

Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.Semantic proximity Read ↗

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.Semantic proximity Read ↗

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.Semantic proximity Read ↗

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarkerSemantic proximity Read ↗

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.Semantic proximity Read ↗

Prognostic Clinical and Radiographic Biomarkers for BRAF-Targeted Therapy in Advanced Melanoma.Semantic proximity Read ↗

NRAS mutation status is an independent prognostic factor in metastatic melanoma.Semantic proximity Read ↗

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.Semantic proximity Read ↗

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.